Skip to main content

Table 2 Summary of ex vivo biodistribution of 124I-scFvD2B in mice with subcutaneous (PSMA)-negative and PSMA-positive xenografts

From: Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

Tissue/organa

EXPERIMENT #4

15 h

24 h

Mean

SD

Mean

SD

Blood

0.028

0.001

0.014

0.003

Tumour pos

1.079

0.166

0.540

0.180

Tumour neg

0.258

0.014

0.135

0.008

Lungs

0.214

0.023

0.216

0.146

Liver

0.017

0.004

0.012

0.005

Spleen

0.036

0.004

0.018

0.003

Pancreas

0.103

0.004

0.059

0.019

Kidney

0.013

0.002

0.005

0.001

Stomach

0.049

0.002

0.047

0.040

Duodenum

0.013

0.003

0.008

0.003

Uro-genital apparatus

0.137

0.044

0.048

0.049

Muscle

0.006

0.000

0.003

0.002

  1. atissue uptake expressed as % ID/g; 2 animals were evaluated at 15 h and 3 animals at 24 h